Evaluation of Bili-ruler, a Low-cost, Plastic Icterometer for Community-based Screening of Jaundice in Newborns

NCT06687746 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5400

Last updated 2026-02-05

No results posted yet for this study

Summary

Newborn jaundice, or accumulation of bilirubin molecules in blood, affects 60-80% of newborns and, in severe cases, places newborns at risk of brain damage and death. Universal screening of all newborn for jaundice ensures that at-risk newborns are identified and treated early. The bili-ruler is a low-cost ($10) plastic icterometer which could enable accurate and timely identification of jaundice in diverse settings.

The objective of this study is to evaluate the ability of bili-ruler to identify jaundiced newborns in their first week of life, compared to traditional methods of jaundice screening: visual inspection and transcutaneous bilirubinometry.

Conditions

  • Jaundice, Neonatal
  • Neonatal Diseases and Abnormalities
  • Neonatal Hyperbilirubinemia
  • Screening Tool
  • Screening

Interventions

DEVICE

Bili-ruler

The noninvasive test will be conducted by aligning the bili-ruler with the infant's nose and choosing the color on the ruler which most closely matches the yellow discoloration on the skin.

Sponsors & Collaborators

  • Kenya Medical Research Institute

    collaborator OTHER
  • University of North Carolina, Chapel Hill

    collaborator OTHER
  • Kintampo Health Research Centre, Ghana

    collaborator OTHER
  • Aga Khan University

    collaborator OTHER
  • Christian Medical College, Vellore, India

    collaborator OTHER
  • Society for Applied Studies

    collaborator OTHER
  • Liverpool School of Tropical Medicine, United Kingdom

    collaborator UNKNOWN
  • University of Ghana

    collaborator OTHER
  • University of North Carolina Global Project Zambia

    collaborator UNKNOWN
  • George Washington University

    lead OTHER

Eligibility

Max Age
28 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2026-04-01
Completion
2026-04-01

Countries

  • Ghana
  • India
  • Kenya
  • Pakistan
  • Zambia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06687746 on ClinicalTrials.gov